Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR.

The human immunodeficiency virus type-1 (HIV-1) Tat activation response (TAR) region is essential for Tat-mediated trans-activation of the HIV-1 long terminal repeat (LTR). The TAR element is present on the 5' and 3' ends of all HIV-1 transcripts and is relatively conserved among different HIV-1 isolates. These properties make it an attractive target for anti-HIV-1 gene therapy strategies. We have constructed a Moloney murine leukemia-based retroviral vector that expresses a chimeric tRNA(iMet)-antisense TAR fusion transcript complementary to the HIV-1 TAR region. The potential of this anti-TAR retroviral vector to inhibit HIV-1 was initially tested by transient transfections with an HIV-1-LTR-Tat expression plasmid into HeLa-CAT cells. Anti-TAR inhibited Tat-mediated HIV-1 LTR-driven CAT reporter gene expression in a dose-dependent fashion. The antisense-TAR vector was then used to transduce the human SupT1 T cell line. Cotransfection of these SupT1 cells with a Tat expression plasmid plus an HIV-1 LTR-CAT reporter plasmid resulted in decreased CAT gene expression in comparison to control transduced SupT1 cells. The antisense-TAR engineered SupT1 cell line was then challenged with HIV-1MN.HIV-1 viral production was inhibited in SupT1 cells transduced with the antisense-TAR retroviral vector. Greater inhibition of HIV-1 was observed with antisense-TAR as compared to antisense-Tat expressing retroviral vector. These observations suggest that antisense-TAR retroviral vectors are potentially useful for clinical anti-HIV-1 gene therapy.

[1]  W. F. Anderson.  Gene therapy for AIDS. , 1994, Human gene therapy.

[2]  J. Lisziewicz,et al.  Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Daucher,et al.  Factors affecting retroviral vector function and structural integrity. , 1993, Virology.

[4]  C. Zhou,et al.  Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes , 1993, Journal of virology.

[5]  Anthony S. Fauci,et al.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease , 1993, Nature.

[6]  H. Temin,et al.  Where has HIV been hiding? , 1993, Nature.

[7]  Ashley T. Haase,et al.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS , 1993, Nature.

[8]  P. Johnson,et al.  Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. , 1992, Science.

[9]  M. Pawlita,et al.  Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis , 1992, Journal of virology.

[10]  A. Frankel.  Activation of HIV transcription by Tat , 1992, Current Biology.

[11]  B. Sullenger,et al.  Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation , 1991, Journal of virology.

[12]  Eli Gilboa,et al.  Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication , 1990, Cell.

[13]  A. Nienhuis,et al.  Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  W. Anderson,et al.  Retroviral vectors expressing soluble CD4: a potential gene therapy for AIDS. , 1990, AIDS research and human retroviruses.

[15]  B. Berkhout,et al.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target , 1989, Cell.

[16]  Andreas Meyerhans,et al.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations , 1989, Cell.

[17]  M. Reitz,et al.  Envelope sequences of two new United States HIV-1 isolates. , 1988, Virology.

[18]  S. Goff,et al.  A safe packaging line for gene transfer: separating viral genes on two different plasmids , 1988, Journal of virology.

[19]  G. Pavlakis,et al.  A quantitative bioassay for HIV-1 based on trans-activation. , 1988, Science.

[20]  J. Ghrayeb,et al.  Expression of the art/trs protein of HIV and study of its role in viral envelope synthesis. , 1987, Science.

[21]  D. Capon,et al.  Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein , 1987, Cell.

[22]  H. Gendelman,et al.  Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[23]  G. Pavlakis,et al.  Expression and characterization of the trans-activator of HTLV-III/LAV virus. , 1986, Science.

[24]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.

[25]  P. Romeo,et al.  Generation of long read-through transcripts in vivo and in vitro by deletion of 3' termination and processing sequences in the human tRNAimet gene. , 1984, Nucleic acids research.

[26]  B. Howard,et al.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells , 1982, Molecular and cellular biology.

[27]  K. Sikora.  Gene therapy--heralding a new era. , 1994, Gene therapy.

[28]  E. Poeschla,et al.  Progress towards gene therapy for HIV infection. , 1994, Gene therapy.